Abstract:Key PointsTumour necrosis factor-related apoptosis-inducing ligand (TRAIL) is a molecule belonging to the tumour necrosis factor (TNF) superfamily. In humans, two TRAIL receptors (TRAIL-R1 and TRAIL-R2) and in mice one receptor (mTRAIL-R) can signal apoptosis upon binding of TRAIL.Induction of apoptosis is enabled through recruitment of the death-inducing signalling complex (DISC). This complex leads to activation of a caspase cascade.TRAIL–TRAIL-R binding can also induce non-apoptotic signalling including via activation of nuclear factor-κB (NF-κB), p38, ERK, SRC and RAC1.Mice deficient in TRAIL or mTRAIL-R are more susceptible to various cancers whereas conditional deletion of mTRAIL-R in Kras- driven cancers ameliorates disease progression. TRAIL–TRAIL-R blockade might therefore be a therapeutic option for patients with KRAS-mutated cancers.TRAIL–TRAIL-R interaction on myeloid-derived suppressor cells in the tumour microenvironment can limit their lifespan and thereby tip the balance towards an antitumour immune environment. Hence, patients with an immunosuppressive cancer microenvironment might benefit from TRAIL-R agonistic therapy.Clinical trials testing an untagged form of recombinant TRAIL, agonistic TRAIL-R1 or TRAIL-R2-specific antibodies or antibody derivatives with higher crosslinking capacity have not led to anticipated therapeutic benefit.Preclinical approaches using therapeutic combinations comprising optimized TRAIL-R agonists and recently discovered powerful apoptosis sensitizers are, however, promising. Therefore, such novel pro-apoptotic combination therapies should be tested in clinical trials.Several drugs, some of which have been approved by the US Food and Drug Administration, induce extrinsic apoptosis through autocrine engagement of the TRAIL–TRAIL-R pathway. Therefore, expression of TRAIL apoptosis pathway components, as well as lack of expression of inhibitors thereof, might be useful for patient selection in clinical trials testing the efficacy of such drugs.

Inelastic scattering and pair breaking in anisotropic and isotropic superconductors.

Molecular Mechanisms of Resistance to TRAIL-induced Apoptosis in Tumor

Overcoming acquired resistance to TRAIL by chemotherapeutic agents and calpain inhibitor I through distinct mechanisms.

TRAIL and Cancer Therapy

The Identification of New c-FLIP Inhibitors for Restoring Apoptosis in TRAIL-Resistant Cancer Cells

17-hydroxy wortmannin restores TRAIL's response by ameliorating increased beclin 1 level and autophagy function in TRAIL-resistant colon cancer cells.

Effects of Different Chemotherapeutic Agents on Reversing the Acquired Resistance to TRAIL Gene in DLD1 Colon Cancer Cells

The Discovery of Small Molecule Inhibitors of cFLIP that Sensitise Tumour Cells to TRAIL

Overcoming acquired resistance to tumor necrosis factor-related apoptosis-inducing ligand by Bcl-XL small interfering RNA in human colon cancer

Triptolide-mediated Downregulation of FLIPS in Hepatoma Cells Occurs at the Post-Transcriptional Level Independently of Proteasome-Mediated Pathways

Exploring the TRAILs less travelled: TRAIL in cancer biology and therapy

Intracellular mechanisms of TRAIL: apoptosis through mitochondrial-dependent and -independent pathways

Novel Molecular Regulators of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (Trail)-Induced Apoptosis in NSCLC Cells

Getting TRAIL back on track for cancer therapy

Over-expression of c-FLIP confers the resistance to TRAIL-induced apoptosis on gallbladder carcinoma.

Pro-Inflammatory Activation Suppresses TRAIL-induced Apoptosis of Acute Myeloid Leukemia Cells

Chemical synthetic approaches to mimic the TRAIL: promising cancer therapeutics

Trailing TRAIL Resistance: Novel Targets for TRAIL Sensitization in Cancer Cells

Resistance to TRAIL is mediated by DARPP-32 in gastric cancer

Enhancing TRAIL-induced apoptosis by Bcl-XL siRNA

The Role of TRAIL Signaling in Cancer: Searching for New Therapeutic Strategies